TLDR LLY stock jumped 4.50% to $1,414.93 following positive Foundayo Phase 3 results.Foundayo cut sleep apnea events by 43.8% among participants without PAP therapy.Patients using PAP therapy saw a 27.5% decline in sleep apnea breathing events.Foundayo delivered average weight loss exceeding 11% across both patient groups.Eli Lilly plans an FDA submission for Foundayo’s sleep apnea use by year-end 2026.Eli Lilly and Company (LLY) shares surged 4.50% to $1,414.93 on Monday, gaining $60.93 following positive Phase 3 clinical results. The stock rebounded from intraday lows near $1,360 as buying pressure strengthened throughout the session. The company reported significant improvements in sleep apnea severity and weight reduction among patients receiving Foundayo.Eli Lilly and Company, LLYEli Lilly Stock Rallies as Foundayo Meets Phase 3 Primary EndpointEli Lilly announced positive results from its ATTAIN-OSA clinical program evaluating Foundayo, also known as orforglipron. The Phase 3 studies examined adults with moderate-to-severe obstructive sleep apnea and obesity or overweight. Researchers evaluated participants who used positive airway pressure therapy and those who received no such treatment.After 52 weeks, Foundayo met its primary endpoint by significantly reducing the apnea-hypopnea index. This measure tracks breathing interruptions during sleep and helps determine the severity of obstructive sleep apnea. The company presented its findings at the American Heart Association Scientific Sessions 2026 and published them in JAMA.Obstructive sleep apnea affects approximately 936 million adults worldwide, although many cases remain undiagnosed. The condition repeatedly interrupts breathing during sleep and increases risks associated with cardiovascular disease. Meanwhile, Eli Lilly continues expanding its cardiometabolic portfolio beyond obesity treatments, including Zepbound.Foundayo Reduces Sleep Apnea Events and Supports Weight LossAmong participants without PAP therapy, Foundayo reduced sleep apnea events by 43.8% after 52 weeks. The treatment lowered breathing interruptions by 21.1 events hourly from an average baseline of 50.7. Additionally, 47.2% of participants achieved reductions of at least 50% in their apnea-hypopnea index.Participants using PAP therapy recorded a 27.5% decline in sleep apnea events during treatment. Furthermore, 33.7% achieved reductions of at least 50%, while 19.6% reached remission or mild disease. Foundayo also reduced oxygen-related sleep apnea burden across both treatment groups.The treatment delivered average weight reductions of 11.5% without PAP therapy and 11.2% with PAP therapy. Participants also recorded improvements in systolic blood pressure and inflammatory markers during the studies. These findings demonstrated benefits across several measures associated with obesity and cardiovascular risk.Eli Lilly Plans FDA Submission Following Positive Trial ResultsEli Lilly plans to submit Foundayo for FDA approval in obstructive sleep apnea by December 2026. The company seeks to expand treatment options for adults with moderate-to-severe disease and excess weight. However, regulators must review the clinical findings before granting approval for this additional indication.The studies identified gastrointestinal symptoms, including nausea, diarrhea, constipation, indigestion and vomiting, as the most common adverse events. Among participants without PAP therapy, 12.2% discontinued Foundayo because of adverse events, compared with 3.8% receiving placebo. Discontinuation rates reached 6.8% with Foundayo and 0.6% with placebo among PAP users.The positive findings strengthen Eli Lilly’s clinical evidence across obesity-related health conditions. Meanwhile, the company’s shares advanced as the results supported another potential treatment opportunity within its cardiometabolic portfolio. The planned FDA submission represents the next regulatory milestone for Foundayo’s sleep apnea indication. The post Eli Lilly and Company (LLY) Stock: Surges 4.50% as Foundayo Delivers Positive Phase 3 Sleep Apnea Results appeared first on Blockonomi.